Abstract:Bromodomains (BRD) are readers of the epigenetic code that regulate gene transcription through their recognition of acetyl-lysine modified histone tails. Recently, bromodomain-containing proteins such as BRD4 have been demonstrated to be druggable through the discovery of potent inhibitors. These protein-protein interaction inhibitors have the potential to modulate multiple diseases by their profound anti-inflammatory and antiproliferative effects. In order to explore new BRD4 inhibitors as well as lead compounds for the development of new drugs, the secondary metabolites of Alternaria sp. NH-F6, a fungus isolated from deep-sea sediment samples, were analyzed systematically. Five new compounds including two new perylenequinones (1-2), one new alternaric acid (3), 2-(N-vinylacetamide)-4-hydroxymethyl-3-ene-butyrolactone (4), one new cerebroside (5), together with 19 known compounds (6-24) were isolated from the ethyl acetate extracts of this strain. Their structures were elucidated using nuclear magnetic resonance (NMR) and high resolution electrospray ionization mass spectrometry (HR-ESI-MS) analyses. Finally, all these compounds were evaluated for their inhibitory activity against BRD4 protein, and compound 2 exhibited a potent inhibition rate of 88.1% at a concentration of 10 µM. This research provides a new BRD4 inhibitor which may possess potential antitumoral, antiviral, or anti-inflammatory pharmaceutical values.

Synthesis and Biological Activity of Quinoxalone Derivatives As Brd4 Bromodomain Inhibitors

Design, Synthesis and Biological Evaluation of Dihydroquinoxalinone Derivatives As BRD4 Inhibitors.

Development of 4,5-Dihydro-benzodiazepinone Derivatives As A New Chemical Series of Brd4 Inhibitors

Inhibitors of BRD4 Protein from a Marine-Derived Fungus Alternaria Sp. NH-F6.

Design, synthesis and biological evaluation of 3,5-dimethylisoxazole and pyridone derivatives as BRD4 inhibitors.

Discovery Of 3,5-Dimethylisoxazole Derivatives As Novel, Potent Inhibitors For Bromodomain And Extraterminal Domain (Bet) Family

Design, Synthesis and Biological Evaluation of Novel 6-Phenyl-1,3a,4,10b-tetrahydro-2h-benzo[c]thiazolo[4,5-e]azepin-2-one Derivatives As Potential BRD4 Inhibitors.

Design, Synthesis, and Biological Evaluation of Quinoxalinone Derivatives As Potent BRD4 Inhibitors.

Design, synthesis and biological evaluation of indole-2-one derivatives as potent BRD4 inhibitors

Design, Synthesis and Biological Evaluation of Imidazolopyridone Derivatives As Novel BRD4 Inhibitors.

Rational Design of 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol Derivatives As Novel Bromodomain-Containing Protein 4 Inhibitors.

Design, synthesis and anticancer evaluation of 3-methyl-1H-indazole derivatives as novel selective bromodomain-containing protein 4 inhibitors

Development of 7-Methylimidazo[1,5-a]pyrazin-8(7h)-one Derivatives As a Novel Chemical Series of BRD4 Inhibitors

Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization and Biological Evaluation.

Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation

Design, Synthesis, and in vitro Biological Evaluation of 3,5-Dimethylisoxazole Derivatives as BRD4 Inhibitors.

Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.

Design, Synthesis and Biological Evaluation of 7-Methylimidazo[1,5-a]pyrazin-8(7h)-one Derivatives As BRD4 Inhibitors.

Design, synthesis, and anticancer evaluation of ammosamide B with pyrroloquinoline derivatives as novel BRD4 inhibitors

Design, Synthesis, and Biological Evaluation of Novel 4,4-Difluoro-1-methyl-n, 6-Diphenyl-5, 6-Dihydro-4h-pyrimido [4, 5-B] [1, 2, 4] Triazolo [4, 3-D] [1, 4] Diazepin-8-amine Derivatives As Potential BRD4 Inhibitors.

Discovery of Novel Coumarin Derivatives As Potent and Orally Bioavailable BRD4 Inhibitors Based on Scaffold Hopping